New Insight with Dr. Veeral Sheth

Don’t Miss a Beat

Crisis Point

Revolutionizing Atopic Dermatitis

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

A new study has found that 1 year of low-dose methotrexate did not reduce pain or effusion-synovitis in patients with 

 suggest an effect of methotrexate for inflammatory hand OA and a potential effect for knee OA. However, they also highlight the importance of phenotyping participants with knee OA to determine which specific populations, if any, will respond favorably to methotrexate. To date, no randomized clinical trial has investigated the efficacy of methotrexate in patients with inflammatory knee OA to our knowledge,” lead investigator Zhaohua Zhu, PhD, Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China, and colleagues wrote.

Zhu and colleagues conducted a multicenter, placebo-controlled randomized clinical trial at 11 sites in China between July 2019, and January 2023. The trial enrolled participants with inflammatory knee OA with effusion-synovitis on magnetic resonance imaging, randomly assigned (1:1) to receive up to 15 mg methotrexate weekly or placebo using block randomization, stratified by study site. The trial primarily assessed knee visual analog scale (VAS) pain change and effusion-synovitis maximal area change over 52 weeks in the intention-to-treat population.

The trial screened 278 participants and randomized 215 participants to methotrexate (n = 108) or placebo (n = 107). Participants had a mean age of 60.4 years (standard deviation [SD], 7.4) and 89% (n = 191) were female. Overall, 175 participants (81%) completed the trial.

The investigators found that there was no significant different between methotrexate and placebo in VAS pain (between-group difference, 0.3 mm [95% CI, −6.7 to 7.3 mm]) or effusion-synovitis maximal area (0.1 cm2 [95% CI, −0.8 to 1.0 cm2]). Additionally, there were no significant between-group differences for any of the prespecified secondary outcomes, including mean change from baseline on the infrapatellar fat pad (IPFP) signal intensity, WOMAC total score, and response rate to therapy, as per OMERACT-OARSI criteria.

Zhu and colleagues did observe significant improvements in VAS pain (between group difference, -40.69 [95% CI, -70.48 to -10.90]), WOMAC pain (between group difference, -176.35 95% CI, -299.08 to -53.61]), function (between group difference, -715.28 95% CI, -1120.02 to 310.55]), and total score (between group difference, -917.26 95% CI, -1457.42 to 377.10]), and general health status (between group difference,-40.08 [95% CI, -64.79 to -15.37]) in participants with severe pain (VAS score ≥ 80 mm) at baseline.

Safety profiles were also comparable between groups, with at least 1 adverse event occurring in 32 participants (29.6%) in the methotrexate group and 26 participants (24.3%) in the placebo group.

Zhu and colleagues acknowledged several limitations of the study, including COVID-19-related recruitment delays, and a small, predominantly female, racially homogeneous population, but stated that follow-up loss and adherence rates were acceptable and balanced between groups.

“In this randomized clinical trial, we found that, compared to placebo, low-dose methotrexate did not relieve pain or reduce the size of effusion-synovitis over 52 weeks in patients with inflammatory knee OA. Further studies are required to confirm if methotrexate has an effect on inflammatory knee OA with severe knee pain,” Zhu and colleagues concluded.

Zhu Z, Yu Q, Leng X, et al. Low-Dose Methotrexate for the Treatment of Inflammatory Knee Osteoarthritis: A Randomized Clinical Trial. JAMA Intern Med. Published online June 02, 2025. doi:10.1001/jamainternmed.2025.1359

WangY﻿, JonesG﻿, KeenHI﻿,et al.Methotrexate to treat hand osteoarthritis with synovitis (METHODS): an Australian, multisite, parallel-group, double-blind, randomised, placebo-controlled trial.﻿Lancet. 2023;402(10414):1764-1772. doi:10.1016/S0140-6736(23)01572-6

Articles

A recent multicenter, placebo-controlled randomized clinical trial investigated the efficacy of low-dose methotrexate in patients with inflammatory knee osteoarthritis (OA) and effusion-synovitis. Conducted across 11 sites in China, the study found no significant difference between methotrexate and placebo in reducing knee pain or effusion-synovitis over 52 weeks. However, significant improvements were observed in patients with severe baseline pain. The study faced limitations, including a small, predominantly female cohort and COVID-19-related recruitment delays. Further research is needed to explore methotrexate's potential effects on severe inflammatory knee OA.

However, a significant effect was seen in a subgroup of participants with severe pain (VAS score ≥ 80 mm) at baseline.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Osteoarthritis

On the HCPLive osteoarthritis page, resources on the topics of medical news and expert insight into OA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on degenerative joint disease, and more.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Methotrexate Not Seen to Have Effect in Knee Osteoarthritis Pain or Effusion-Synovitis

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Paula Tanabe, PhD | Image Credit: Department of Medicine, Duke University School of Medicine

A recent retrospective cohort study seeking to redefine high emergency department (ED) utilization as a result of 

 described 4 new categories of ED utilization that may allow for the reframing of how ED use is determined.

SCD affects roughly 100,000 individuals in the US alone. Associated with a severely shortened lifespan, prior studies have indicated that patients with SCD have a median death age of 43 years. The most common complication of SCD is severe painful events, known as vaso-occlusive episodes (VOEs). Increases in VOE frequency per year has also been associated with increased risk of mortality.

Between 1999 and 2020, there were roughly 4.9 million ED visits for SCD in the US – 75% of these were for treatment of VOEs. Roughly 222,612 occurred annually during this timeframe, noted as a nearly 13% increase from previous estimates. Additionally, over half of surveyed patients reported utilizing the ED for severe levels of pain consistent with VOEs.

“Understanding actual utilization based on data for individuals with SCD is important as it will allow for early identification of potential changes in utilization for an individual patient,” wrote Paula Tanabe, PhD, Duke University School of Medicine, and colleagues. “Clinicians can then begin to investigate reasons for utilization changes with the patient earlier.”

Tanabe and colleagues utilized the statewide, all-payer North Carolina Hospital Discharge Data, collecting data from 2012-2020. Participants were included if they had SCD defined as 3 or more visits – ED, inpatient, or outpatient surgery. A collective 9964 patients with SCD were initially included – however, 269 patients died in a healthcare facility during the study period. Mean (standard deviation [SD]) age was 24.49 (17.54) years. The total included 9355 Black patients (93.89%).

The main outcome of the study was annual ED visits between 2013 and 2019; these were defined as any ED visit, including treat-and-release ED discharges and admissions to the hospital. Demographic variables, such as age, sex, race, and ethnicity, were extracted from visit-level data. The 2020 state-ranked Social Vulnerability Index (SVI) was utilized to measure socioeconomic factors linked with ED visits at the county level. The SVI ranks counties on 16 social factors under 4 themes; socioeconomic status, household characteristics, racial and ethnic minority status, and housing type and transportation.

In total, included patients had 100,188 ED visits from 2013-2019. These were categorized into 4 levels: low (0-1 visits/year), moderate (2-9 visits/year), high (10-32 visits/year), and super high (≥33 visits/year), with 3397 participants (34.09%) in low, 5631 participants (56.51%) in moderate, 758 participants (7.61%) in high, and 178 participants (1.79%) in super high. The team notes that <10% of participants contributed to 55% of all ED visits: more specifically, 178 participants contributed 27,358 ED visits (27.3%) and 758 contributed 28,124 (28.1%). Nearly 1 in 3 ED visits (31,406 [31.35%]) resulted in hospitalizations, with a mean (SD) stay of 5.1 (4.6) days.

Age was also significantly associated with ED visit grouping. Compared to younger age groups (e.g. age <19 years), older groups were more likely to have moderate (age 19-39 years: odds ratio [OR] 2.07; 95% CI, 1.88-2.29; age ≥40 years: OR 1.22; 95% CI, 1.09-1.37) or high (age 19-39 years: OR 6.09; 95% CI, 4.98-7.46; age ≥40 years; OR 1.57; 95% CI, 1.2-2.05) ED utilization versus low ED utilization. However, the young adult group was 16 times more likely to have super high ED utilization (OR 16.44; 95% CI, 9.75-27.72) versus low.

Despite the clear-cut appearance of the results, Tanabe and colleagues note a few limitations with the study. First, investigators were unable to examine previously identified risk factors for high ED utilization, such as clinical characteristics representative of medical (acute chest syndrome, transfusions) and psychiatric (anxiety, depression) morbidity or chronic opioid therapy use. Second, dataset limitations resulted in a lack of specificity to determine disease severity or complications.

“As these visits approach the high and super high categories, ED clinicians should be brought into the conversation, and specific plans should be available in the electronic health record to guide ED management,” Tanabe and colleagues wrote. “Often, these patients will have complex medical, social, and behavioral health needs.”

Tanabe P, Pan W, Blewer AL, et al. Redefining High Emergency Department Utilization for Sickle Cell Disease. JAMA Netw Open. 2025;8(6):e2513361. doi:10.1001/jamanetworkopen.2025.13361

Hassell KL. Population estimates of sickle cell disease in the U.S. American Journal of Preventive Medicine. 2010;38(4). doi:10.1016/j.amepre.2009.12.022

Attell BK, Barrett PM, Pace BS, et al. Characteristics of emergency department visits made by individuals with sickle cell disease in the U.S., 1999–2020. AJPM Focus. 2023;3(1):100158. doi:10.1016/j.focus.2023.100158

A retrospective cohort study redefined high emergency department (ED) utilization in sickle cell disease (SCD) by introducing four new categories of ED use. SCD affects approximately 100,000 individuals in the US, with a median death age of 43 years. The study analyzed data from 2012-2020, including 9964 patients, and categorized ED visits into low, moderate, high, and super high levels. Findings revealed that a small percentage of patients accounted for the majority of ED visits. Age was significantly associated with ED visit frequency, with young adults showing the highest utilization.

Investigators examined emergency department utilization as a product of age, patient-reported severity of vaso-occlusive episodes, and Social Vulnerability Index score.

Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

High Emergency Department Use for Sickle Cell Disease Recharacterized in New Study

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Diabetes Dialouge: May 2025 Diabetes Tech & Breakthrough T1D Updates

, co-hosts hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss significant developments in diabetes care from May 2025, including Medtronic’s restructured business model, Sequel Twiist’s technological collaboration with Abbott, and Breakthrough T1D’s efforts to advance early detection of 

The discussion opens with news of Medtronic’s decision to spin off its diabetes division into a standalone entity, currently referred to as “New Diabetes Company.” While the final name is forthcoming, the move is intended to streamline operations and accelerate innovation within the diabetes space. The hosts highlight the company’s promising technology pipeline, including the forthcoming 800 series insulin pump with full smartphone control and plans for a tubeless insulin delivery system. Both experts express optimism that the independence may foster greater agility in product development, enhance accessibility, and maintain a focus on user-centered design, including for populations with visual impairments.

Next, Isaacs and Bellini examine the announcement of the Sequel Twiist partnership with Abbott to integrate continuous ketone monitoring (CKM) into a hybrid sensor, which is expected to function similarly to the FreeStyle Libre 3. This device, still in development, will provide real-time data on both glucose and ketone levels—a critical advance for people with type 1 diabetes using insulin pumps, who are at elevated risk for diabetic ketoacidosis (DKA). While excited about the potential for earlier DKA detection, Bellini emphasizes the importance of cost-effective implementation and integration with existing pump platforms.

The episode concludes with coverage of Breakthrough T1D’s advocacy before the US Preventive Services Task Force to support routine screening for T1D autoantibodies. The goal is to identify individuals in early stages of the disease to prevent DKA and misdiagnosis. The hosts note that despite advancements in understanding T1D progression, many patients remain undiagnosed until presenting with DKA or are mistakenly classified as having 

Medtronic plc. Medtronic announces intent to separate Diabetes business. Medtronic News. Published May 21, 2025. Accessed June 2, 2025. 

https://news.medtronic.com/2025-05-21-Medtronic-announces-intent-to-separate-Diabetes-business

Sequel Med Tech. Sequel Med Tech to Integrate twiist Automated Insulin Delivery (AID) System with Abbott’s Future Dual Glucose-Ketone Sensor. GlobeNewswire News Room. Published May 22, 2025. Accessed June 2, 2025. 

https://www.globenewswire.com/news-release/2025/05/22/3086535/0/en/Sequel-Med-Tech-to-Integrate-twiist-Automated-Insulin-Delivery-AID-System-with-Abbott-s-Future-Dual-Glucose-Ketone-Sensor.html

Breakthrough T1D. Breakthrough T1D Submits Application to Make Screening for Type 1 Diabetes Part of Recommended Preventive Services in the US - Breakthrough T1D. Breakthrough T1D. Published May 21, 2025. Accessed June 2, 2025. 

https://www.breakthrought1d.org/for-the-media/press-releases/breakthrough-t1d-submits-application-to-make-screening-for-type-1-diabetes-part-of-recommended-preventive-services-in-the-us/

Podcasts

Hosts breakdown diabetes technology updates from May 2025 and Breakthrough T1D's push for improved screening.

Type 2 Diabetes

Type 1 Diabetes

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Naveed Sami, MD, a board-certified dermatologist and Professor of Medicine at the UCF College of Medicine, spoke at the 

 in a session titled “Cutaneous Effects of Immunotherapy.”

 editorial team asked Sami to summarize some of the most notable takeaways from this talk at the conference. Sami highlighted some of his session’s most significant points, noting them in order of their description during his talk.

Addressing the Cutaneous Effects of Immunotherapy, with Naveed Sami, MD

“The first [point] is really recognizing the fact that immunotherapies are becoming an increasing part in the treatment of cancers,” Sami explained. “Because they're increasing use, we probably will be seeing more side effects…because there are different targeted therapies, they have different side effects. So it's important to be aware when certain side effects come about in the skin…The second is focusing on three main immunotherapies from which we may see side effects. And the third is discussing their evaluation and [ways to] approach evaluating the patient who does present with a cutaneous side effect.”

Sami noted the importance of recognizing such an issue early on, adding that early recognition can help to prevent these side effects if treated appropriately. He was asked to go into greater depth about these takeaways.

“We focused on three of the major categories [of immunotherapies],” Sami said. “The first one is called immune checkpoint inhibitors…What happens with immune checkpoint inhibitors is it's the ‘brakes’ are removed, so there are immune cells that can go after a cancer cell. When that happens, the regulation is sometimes not as good, and when that happens is we see a lot of immune-mediated issues in the skin.”

Sami highlighted that conditions such as psoriasis, eczema, vitiligo, or bullous pemphigoid can appear in such cases. He added that more severe reactions can occur at any point from the outset, such as toxic epidermal necrolysis or drug hypersensitivity syndrome.

“The second [cateogry] is what I call the acneiform eruptors,” Sami said. “There are MEK inhibitors and [Epidermal Growth Factor Receptor] inhibitors. Those can cause an acne-like rash, which can be very painful at times but can also be prevented. So if a patient is about to go on those treatments, they can be put on some acne systemic treatments, such as doxycycline, to prevent that from happening.”

Sami highlighted that even if such patients are put on doxycycline, if it is not working, topical treatments or even isotretinoin can be implemented.

“The third is the BRAF inhibitors,” Sami explained. “The BRAF inhibitors have a side effect of skin cancer, or squamous cell carcinoma specifically. Fortunately, these are not very aggressive, so we can help in their treatment, but they can also be prevented by using the MEK inhibitors, potentially to prevent the side effects of BRAF inhibitors. We see, for many of the side effects that BRAF inhibitors cause, that if you have an adjuvant treatment with MEK inhibitors, you can minimize those kinds of side effects, and sometimes you can actually reverse them.”

For any additional information on the topics discussed in this interview, view the full video segment posted above.

The quotes used in this video summary were edited for the purposes of clarity.

Videos

In this interview at the New Wave Dermatology meeting, Naveed Sami, MD, highlights some of the notable takeaways from his talk on the impacts of immunotherapies.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

As we move through 2025, new research is advancing our understanding of 

 and food hypersensitivity. Recent studies identify GDNF, IL-18R1, and IL-15RA as promising biomarkers in seasonal allergic rhinitis. Meanwhile, evidence points to age 2 as the optimal timing for hen’s egg oral food challenges in FPIES. These insights highlight the need for personalized, population-specific allergy management.

This allergy month in review captures recent discoveries, the US Food and Drug Administration (FDA) warning of severe itching after stopping cetirizine or levocetirizine, and what is driving the rise in food allergies.

FDA Warns About Rare, Severe Itching After Stopping Cetirizine or Levocetirizine

The FDA announced on May 16, 2025, that a pruritus risk warning will be added to cetirizine and levocetirizine labels after identifying 209 global cases, mostly in the US, of severe itching following discontinuation after long-term use. Though rare, symptoms may require medical care and often resolve if treatment is resumed. Clinicians should inform patients of this risk, particularly when recommending prolonged use of these allergy medications.

FDA Accepts BioCryst’s NDA for Berotralstat Oral Granules in Children With HAE

The FDA accepted BioCryst’s NDA for berotralstat oral granules in children aged 2 – 11 years with hereditary angioedema (HAE) and granted priority review, with a target action date of September 12, 2025. If approved, it would be the first oral prophylactic therapy for this age group, offering a more convenient option to help prevent serious HAE attacks.

New Guidelines Outline When to Consider Sinus Surgery for Chronic Rhinosinusitis

New guidelines from the American Academy of Otolaryngology outline 11 evidence-based steps for deciding when sinus surgery is appropriate in adults with chronic rhinosinusitis. Emphasizing diagnosis confirmation, appropriate imaging, and shared decision-making, the recommendations support surgery when benefits outweigh medical therapy, particularly for patients with polyps, fungal infections, or worsening conditions like asthma. Antibiotic overuse is discouraged.

Microbes, Medicine, Modern Life May Drive Food Allergy Rise, Experts Say

Food allergies have surged 50% since the 1990s, now affecting 33 million Americans. Experts link the rise to delayed allergen introduction, microbiome changes, antibiotic use, C-sections, and environmental factors. Early allergen exposure is now advised. Still, uncertainty remains, prompting calls for more research, revised clinical practices, and anxiety management around food allergies in both patients and providers.

How To Go About Proximity Challenges for Food Allergy Anxiety in the Clinic

Proximity challenges help patients with food allergy anxiety safely confront fears and distinguish anxiety from true allergic reactions. Experts recommend assessing avoidance behavior and using targeted questions and scales. These challenges boost coping skills, correct misconceptions, and improve daily functioning. Homework and tailored strategies support lasting fear reduction across all ages.

How to Address Food Allergy Anxiety with Proximity Challenges

New National Push to Improve Anaphylaxis Response in Childcare Centers, with Alice Hoyt, MD

The Early Childhood Anaphylaxis Collaborative aims to improve anaphylaxis recognition and response in childcare centers. With food allergies rising in children under 5, the initiative promotes training, awareness of atypical symptoms, and access to stock epinephrine. HCPLive spoke with Alice Hoyt, MD, chair of Code Ana, a founding partner of the collaborative, who emphasized the need for early education to prevent delayed treatment of potentially life-threatening allergic reactions.

GDNF, IL-18R1, IL-15RA Identified as Novel Biomarkers in Seasonal Allergic Rhinitis

A new study identified GDNF, IL-18R1, and IL-15RA as novel biomarkers strongly linked to seasonal allergic rhinitis symptoms. These inflammation-related proteins fluctuated with allergy seasons and correlated with nasal symptoms. As urbanization drives rising allergic rhinitis cases, these findings may advance targeted diagnostic tools and therapies by uncovering molecular pathways involved in immune response and symptom development.

Optimal Timing for Hen’s Egg Oral Food Challenge in FPIES May Be Age 2 Years

A new study suggests age 2 is the optimal time for a hen’s egg oral food challenge (OFC) in children with FPIES in Turkey. Earlier OFCs were linked to greater risk of positive reactions. While remission timing varies globally, this research supports population-specific guidelines to reduce unnecessary food restrictions and improve tolerance assessment strategies.

Recent advancements in allergy and food hypersensitivity research have identified GDNF, IL-18R1, and IL-15RA as potential biomarkers for seasonal allergic rhinitis. The FDA has issued a warning about severe itching after discontinuing cetirizine or levocetirizine and accepted BioCryst’s NDA for berotralstat oral granules for children with HAE. New guidelines for sinus surgery in chronic rhinosinusitis emphasize evidence-based decision-making. Experts attribute the rise in food allergies to various factors, advocating for early allergen exposure and improved anaphylaxis response in childcare settings.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Allergy Month in Review: May 2025

This May was characterized by HCPLive’s coverage of the ARVO and Envision conferences, as well as a slew of FDA approvals towards the end of the month.

FDA News

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Diabetic Macular Edema

The HCPLive diabetic macular edema page is a comprehensive resource for clinical news and insights on DME. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the leading cause of blindness, and more.

Uveitis

The HCPLive uveitis page is a comprehensive resource for clinical news and insights on chorioretinitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for eye inflammation, and more.

Geographic Atrophy

Age-Related Macular Degeneration

age-related macular degeneration condition center page is a comprehensive resource for clinical news and insights on retina disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for patients with AMD.

Ophthalmology Month in Review: May 2025

A new study reveals immersive virtual reality exercise reduces perceived pain in fibromyalgia patients, highlighting its potential for chronic pain management.

Fibromyalgia

On the HCPLive fibromyalgia page, resources on the topics of medical news and expert insight into fibrositis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on fibromyalgia, and more.

VR-Based Exercise Reduces Perceived Pain Intensity, Mechanical Pain Sensitivity Persists in Fibromyalgia

Lyra Therapeutics announced LYR-210 met primary and secondary endpoints in phase 3 ENLIGHTEN 2, improving CRS symptoms and showing strong safety.


LYR-210 Nasal Implant for CRS Brings Symptom Relief in Phase 3 ENLIGHTEN 2

Vera Therapeutics intends to bring the results before the FDA by the end of 2025; they anticipate an approval and commercial launch in 2026.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Atacicept Achieves Endpoints in Phase 3 ORIGIN Trial for IgA Nephropathy

This Month in Review summary includes a list of some of the most notable or impactful news in the dermatology field from May 2025.

Alopecia

Dermatology Month in Review: May 2025

Panelists discuss how understanding the causes of iron deficiency in pregnancy, selecting appropriate supplementation strategies, and collaborating between obstetrician-gynecologists and hematologists are crucial for effective management and ensuring optimal care for pregnant women.

Medcast Podcasts

Addressing Iron Deficiency Anemia in Women’s Health: Insights for the OB/GYN Practice 

Ahmad Masri, MD, MS, is the director of the Hypertrophic Cardiomyopathy Center at Oregon Health and Science University. 

Panelists discuss how future clinical trials in transthyretin amyloid cardiomyopathy (ATTR-CM) should focus on incorporating mechanistic research, patient stratification, and diverse end points, while also including nonresponders to current therapies to better understand cardiac dysfunction and develop more personalized treatment strategies.

Video Series

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

A Look Into the Future of ATTR-CM Clinical Trials

Panelists discuss how monitoring clinical indicators, cardiac imaging, biomarkers, and functional assessments—such as NT-proBNP, troponin, and the 6-minute walk test—helps detect progression in transthyretin amyloid cardiomyopathy (ATTR-CM), allowing for early intervention and optimal disease management.

Prognostic Indicators of Disease Progression in ATTR-CM

Ruben Colman, MD, PhD: Director of Intestinal Ultrasound at Stanford University

Point-of-care intestinal ultrasound offers real-time, noninvasive monitoring for pediatric IBD, enabling faster, personalized treatment decisions in routine care.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Faster, Targeted Pediatric IBD Care with Point-of-Care Ultrasound

Panelists discuss how long-term monitoring in transthyretin amyloid cardiomyopathy (ATTR-CM) involves regular clinical assessments, imaging studies, and biomarker evaluations—such as NT-proBNP, troponin, and TTR testing—to track disease progression, manage complications, and optimize patient outcomes.

Latest News

Methotrexate Not Seen to Have Effect in Knee Osteoarthritis Pain or Effusion-Synovitis

High Emergency Department Use for Sickle Cell Disease Recharacterized in New Study

Diabetes Dialouge: May 2025 Diabetes Tech & Breakthrough T1D Updates

Addressing the Cutaneous Effects of Immunotherapy, with Naveed Sami, MD

Allergy Month in Review: May 2025